EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma

Ying-Hsin Chen, Wei-Feng Li, Yen-Hao Chen, Ming-Chao Tsai, Yuan-Hung Kuo, Jing-Houng Wang, Chien-Hung Chen, Sheng-Nan Lu, Chih-Chi Wang, Chao-Hung Hung iD

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04476-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Ying-Hsin Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medi…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized, Bevacizumab. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAntibodies, Monoclonal, HumanizedBevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedPrognosisHepatectomyTreatment Outcome

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabCurative therapyHepatocellular carcinomaOverall survivalProgression-free survival

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabBevacizumab

Autor:innen und Institutionen

  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
  • Liver Transplant Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan. chh4366@yahoo…

ORCID-Profile: Chao-Hung Hung

Förderung

  • National Science Council

Zitieren

APA

Chen, Y. H., Li, W. F., Chen, Y. H., Tsai, M. C., Kuo, Y. H., Wang, J. H., Chen, C. H., Lu, S. N., Wang, C. C., & Hung, C. H. (2026). Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04476-y

Vancouver

Chen YH, Li WF, Chen YH, Tsai MC, Kuo YH, Wang JH, et al. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04476-y

BibTeX
@article{Chen2026,
  author = {Chen, Ying-Hsin and Li, Wei-Feng and Chen, Yen-Hao and Tsai, Ming-Chao and Kuo, Yuan-Hung and Wang, Jing-Houng and Chen, Chien-Hung and Lu, Sheng-Nan and Wang, Chih-Chi and Hung, Chao-Hung},
  title = {Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04476-y}
}
Kostenlos starten →